GeneDx Holdings에 대한 매도 수량은 투자자에게 GeneDx Holdings의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

GeneDx Holdings (NASDAQ:WGS) 주식, 공매도 수량 보고

GeneDx Holdings

GeneDx Hldgs

GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.

Uber Weride

Equities

Mid Cap

News

Movers

Trading Ideas

AXSM

CRSP

MKGAF

MKKGY

NVDA

RXRX

SWTX

TEVA

VNET

이들 10개 대형주는 지난 주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 위라이드(NASDAQ:WRD)의 주식이 97.62% 급등했다. 이는 엔비디아(NASDAQ:NVDA)가 13F 제출을 통해 174만 주의 지분을 보유하고 있다고 공개한 후 발생한 일이다.

위라이드, 크리스퍼 및 진DX 등 지난주 최대 상승한 10개의 중형주 (2월 10일-2월 14일)

5 Stocks To Watch Heading Into Tuesday

Earnings

Pre-Market Outlook

Markets

LFCR

SPSC

미국 주식 선물이 금요일 아침 (현지 시간 기준) 상승하고 있는 가운데, 오늘 투자자들의 관심을 끌 수 있는 주식들은 다음과 같다: 진디엑스 홀딩스(NASDAQ:WGS)는 브라이언 디카이로(Bryan Dechairo)를 COO로 임명했다고 발표했다. 진디엑스 주식은 애프터 마켓에서 2.7% 하락하여 $77.46에 거래되었다.

금요일 주목해야 할 주식: 리소스 커넥션, SPS 커머스, 라이프코어, 진디엑스 및 UDR

GSAT

Topics

AAPL

MDGL

OMCL

PRCT

이들 7개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 마드리갈 파마슈티컬스(NASDAQ:MDGL)의 주식은 회사가 예상보다 좋은 실적을 발표한 후 51.70% 상승했다.

글로벌스타와 넥스트래커는 지난주 최고 성과를 보여준 7개 중형주 중 일부 (10월 28일-11월 1일)

GeneDx Holdings Corp. - Class A Common Stock

GeneDx Holdings Corp

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Verona Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>) with a Buy and raises the price target from $85 to $90.

Price Target

Analyst Ratings

VRNA

HC Wainwright & Co. Maintains Buy on Verona Pharma, Raises Price Target to $90

– Multiple Subgroup Analyses Presented From Long-Term Safety Study of LYBALVI&#xAE; (olanzapine and samidorphan), Including Data on Lipid and Glycemic Profiles –
DUBLIN, June 2, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439097-1&amp;h=841886729&amp;u=https%3A%2F%2Fwww.alkermes.com%2F&amp;a=Alkermes+plc">Alkermes plc</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) today announced the presentation of accepted research at key scientific conferences this spring, including presentations largely related to its psychiatry products LYBALVI&#xAE; (olanzapine and samidorphan) and ARISTADA&#xAE; (aripiprazole lauroxil). Several of these meetings coincided with Mental Health Awareness Month in May, an important moment to raise awareness about mental health conditions, support the millions of people living with these complex diseases, and acknowledge the critical work of healthcare providers. The meetings included:
<ul>
<li>American Association of Psychiatric Pharmacists (AAPP) Annual Meeting, April 27-30, Salt Lake City</li>
<li>The Neuroscience Education Institute (NEI) Spring Congress, May 8-10, Philadelphia</li>
<li>The Professional Society for Health Economics and Outcomes Research (ISPOR) Annual Conference, May 13-16, Montreal</li>
<li>American Psychiatric Association (APA), May 17-21, Los Angeles</li>
<li>American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, May 27-30, Scottsdale</li>
<li>Psych Congress Elevate, May 28-31, Las Vegas</li>
</ul>

ALKS

Alkermes Highlights LYBALVI And ARISTADA Data At Key Scientific Conferences

<ul>
<li>ENLIGHTEN 2 trial met primary endpoint with LYR-210 demonstrating statistically significant improvement in the composite of the three cardinal symptoms (3CS) of CRS at 24 weeks (p=0.0078).</li>
<li>ENLIGHTEN 2 trial also showed statistically significant improvement in key secondary endpoints in the full population of 3CS at 24 weeks (p=0.0209) and SNOT-22 score at 24 weeks (p=0.0101).</li>
<li>Additionally, in pooled data from ENLIGHTEN 2 and ENLIGHTEN 1 trials in 64 CRS patients with nasal polyps, LYR-210 demonstrated a consistent positive trend over 24 weeks in multiple key efficacy endpoints.</li>
<li>Lyra plans to review the totality of the dataset from the ENLIGHTEN trials to evaluate next steps for pursuing an indication in non-polyp patients, as well as to continue development of LYR-210 in patients with nasal polyps&nbsp;&nbsp;</li>
</ul>

Biotech

Health Care

General

LYRA

Lyra Therapeutics' ENLIGHTEN 2 Phase 3 Trial Of LYR-210 For Chronic Rhinosinusitis Met Its Primary Endpoint, With LYR-210 Demonstrating Statistically Significant Improvement Compared To Sham Control In A Composite Of The Three Cardinal Symptoms

Keybanc analyst Christopher Carril initiates coverage on Shake Shack (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>) with a Sector Weight rating.

Initiation

SHAK

Keybanc Initiates Coverage On Shake Shack with Sector Weight Rating

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4438958-1&amp;h=1951662543&amp;u=https%3A%2F%2Fwww.anixa.com%2F&amp;a=Anixa+Biosciences%2C+Inc.">Anixa Biosciences, Inc.</a> ("Anixa" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIX#NASDAQ">ANIX</a>), a biotechnology company focused on the treatment and prevention of cancer, today announced the completion of enrollment in the Phase 1 clinical trial of its breast cancer vaccine. This novel vaccine, invented at Cleveland Clinic, is also being developed in partnership with Cleveland Clinic and the Phase 1 trial is fully funded by a grant from the U.S. Department of Defense (DoD).
The vaccine is designed to stimulate the immune system to target breast cancer before it can recur or develop. A total of 35 women have received the vaccine in the trial, including 26 in the triple-negative breast cancer ("TNBC") group, four in the prevention group, and five in the pembrolizumab group. These participants represent three distinct patient cohorts:
<ul>
<li>TNBC Group: Women who have completed treatment for triple-negative breast cancer, are currently cancer-free, and are at risk of recurrence.</li>
<li>Prevention Group: Women who are cancer-free but carry genetic mutations that place them at high risk of developing breast cancer and have elected to undergo preventative mastectomy to lower their risk.</li>
<li>Pembrolizumab (Keytruda) Group: Women who are receiving pembrolizumab in a post-operative setting. These women are receiving the vaccine concurrently with pembrolizumab.</li>
</ul>
The final patient visits are scheduled for August 2025. Once completed, the final study report will be submitted to the Department of Defense. A Clinical Study Report (CSR) will then be prepared for submission to the U.S. Food and Drug Administration. As part of the continued development process, the Investigational New Drug (IND) application will be transferred from Cleveland Clinic to Anixa.
Anixa and Cleveland Clinic plan to submit for presentation all trial data at a major upcoming scientific meeting.
Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, commented, "We are very encouraged by the data we are seeing from this trial. Preliminary results show that our breast cancer vaccine is well tolerated, with more than 70% of patients demonstrating protocol-defined immune responses. These encouraging findings are guiding our planning for Phase 2 trials, which will include discussions with the FDA, protocol development, manufacturing, and clinical site selection. While cancer vaccines have traditionally faced significant hurdles, our approach is aimed at a novel target that has not been previously explored in this context. We believe this could represent a new paradigm in immuno-oncology. The breast cancer market, particularly for triple-negative breast cancer and genetically high-risk populations, continues to face a major unmet need. Our vaccine may offer a unique, immunologic pathway for both prevention and treatment."

ANIX

Anixa Biosciences Completes Enrollment In Phase 1 Clinical Trial Of Breast Cancer Vaccine

Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer
Data continue to support planned initiation of pivotal study in mid-2025
Next-generation triplet combinations with atirmociclib (CDK4-selective) &amp; ribociclib ongoing
CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Q0gTYYh0XNKiOiXKmI9gOsksgI8_wm3UouToi--Ehs1OVKagdDy56xsgmUueh0KPLXKLq3UXdZWqkn1HfkN7zoYBDDMyYEFAEORjJWyVHIQ=">Relay Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLAY#NASDAQ">RLAY</a>), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced updated interim clinical data for RLY-2608, the first known investigational allosteric, pan-mutant and isoform-selective inhibitor of PI3Kα. The updated data have a median duration of follow-up of 12.5 months and remain consistent with data shared in December 2024. They show a median progression free survival (PFS) of 11.0 months in second line (2L) patients with PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast cancer who received RLY-2608 600mg twice daily (BID) + fulvestrant. These data are being presented today at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting.

RLAY

Relay Therapeutics Says Updated Interim Clinical Data For RLY-2608 Remain Consistent, Showing 10.3-Month Median PFS Overall And 11.0-Month Median PFS In 2L Patients With PI3Kα-Mutated, HR+/HER2- Metastatic Breast Cancer

Paul Buchheit, the engineer behind Gmail, once challenged the popular wisdom in tech product development with an essay where he argued that a "great" product needs to do only a few things very well.
What Happened: In a 2010 blog <a href="https://paulbuchheit.blogspot.com/2010/02/if-your-product-is-great-it-doesnt-need.html?utm_source=www.founderstribune.org&amp;utm_medium=referral&amp;utm_campaign=if-your-product-is-great-it-doesn-t-need-to-be-good-by-paul-buchheit">post</a>, Buchheit discussed the common criticism of the first iPad, noting that the backlash echoed early responses to the iPod.
"The negative responses are so perfectly misguided that it would be wrong to waste this opportunity," he wrote. He referred to a now-famous Slashdot review of the iPod that read: "No wireless. Less space than a nomad. Lame." Similar critiques of the iPad focused on what it did not have rather than what it did well.
Buchheit wrote that successful products didn't win by piling on features. "Those missing features are typically available in a variety of unsuccessful competing products," he wrote.
He illustrated his point by citing Gmail's stripped-down launch: "It was fast, stored all of your email (back when 4MB quotas were the norm), and had an innovative interface based on conversations and search."
He recalled that even the address book, a feature many considered fundamental, was built in just two days. "The engineer doing the work originally wanted to spend five days on it, but I talked him down to two since I never use that feature anyway," he noted.
See Also: <a href="https://www.benzinga.com/markets/equities/25/06/45714138/vinod-khosla-tells-google-forget-about-search-sun-microsystems-co-founder-urges-tech-giant-to-invest-tens-of-billions-in-self-driving-before-others-catch-up">Vinod Khosla Tells Google Forget About Search, Sun Microsystems Co-Founder Urges Tech Giant To Invest &#8216;Tens Of Billions&#8217; In Self-Driving Before Others Catch Up</a>
Why It Matters: Buchheit articulated his belief that the "more features = better" mindset led otherwise smart people to build bad products.
"If a MacBook with OSX and no keyboard were really the right product, then Microsoft would have already succeeded with their tablet computer years ago," he observed. Instead, he urged creators to narrow their focus and execute well: "Pick three key attributes or features, get those things very, very right, and then forget about everything else."
"If your product needs ‘everything' in order to be good, then it&#8217;s probably not very innovative," he warned. "Put another way, if your product is great, it doesn&#8217;t need to be good." In his view, solid products succeeded not by being exhaustive, but by excelling at the essentials.
Despite Buchheit's references to Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) products, his speedy approach seems to contrast the company's visionary co-founder <a href="https://www.benzinga.com/general/24/04/38403093/steve-jobs-spent-hour-after-hour-on-product-design-he-cared-about-god-being-in-the-details-says-walt">Steve Jobs' process of dedicating "hour after hour" to product design.</a>
Earlier this year, Microsoft Corp. Co-founder <a href="https://www.benzinga.com/tech/25/02/43577868/bill-gates-says-steve-jobs-once-told-him-i-wish-youd-take-acid-that-would-enhance-microsofts-product-design-more-i-envy-those-skills-im-not-in-his-league">Bill Gates even shared an anecdote</a> about how Jobs suggested that he do hallucinogenic drugs to have &#8220;more taste&#8221; when designing Microsoft products.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/topics/25/06/45712700/apples-ai-struggles-to-keep-pace-with-rivals-ahead-of-wwdc-2025">Apple&#8217;s AI Struggles To Keep Pace With Rivals Ahead Of WWDC 2025</a></li>
</ul>
Photo courtesy: Koshiro K / Shutterstock.com

Tech

MSFT

'If Your Product Is Great, It Doesn't Need To Be Good:' When Gmail Creator Paul Buchheit Took Aim At Tech's Obsession With Features

Retirees who have defaulted on their student loans may see a reduction in their Social Security checks from June. This is a result of&nbsp;the U.S. Department of Education&#8217;s decision to recommence involuntary collections on defaulted student loans, including garnishing wages, intercepting tax refunds and seizing a portion of Social Security benefits.
What Happened: The U.S. Department of Education is set to recommence collection activity on the nation&#8217;s $1.6 trillion student loan portfolio, after a nearly five-year pause due to Covid-era policies. According to the <a href="https://www.cnbc.com/2025/06/01/social-security-checks-student-loan-garnishments-begin.html">CNBC</a> report, the garnishments will start in June and the affected retirees may receive reduced Social Security checks from this month onwards.
As per Forbes, several retirees could see their monthly Social Security checks reduced significantly, in some cases down to just $750. However, the actual reduction will depend on factors such as the recipient&#8217;s birth date and when they began receiving benefits.
However, according to&nbsp;Nancy Nierman, assistant director of&nbsp;the Education Debt Consumer Assistance&nbsp;Program in New York, borrowers have options to halt these payment offsets.
Higher education expert Mark Kantrowitz states that federal student loan borrowers should have been given at least 30 days' notice before their Social Security benefits were offset. He notes that borrowers can avoid or halt the offset by proving financial hardship or having a pending loan discharge.
Meanwhile, Betsy Mayotte, president of&nbsp;The Institute of Student Loan Advisors, suggests that opting for an income-driven repayment plan could be a way out. Borrowers with severe, permanent mental or physical disabilities that prevent them from working may qualify for a Total and Permanent Disability (TPD) discharge, using proof from a doctor, the SSA, or the VA, suggest experts. 
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/economic-data/25/06/45715685/howard-lutnick-calls-1-2-trillion-trade-deficit-a-national-emergency-says-trumps-tariffs-are-not-going-away" target="_blank" rel="noreferrer noopener">Howard Lutnick Calls $1.2 Trillion Trade Deficit A &#8216;National Emergency,&#8217; Says Trump&#8217;s Tariffs Are &#8216;Not Going Away&#8217; &#8211; Benzinga</a>
Why It Matters: The resumption of involuntary collections on defaulted student loans is part of a broader trend of financial challenges facing retirees. The Consumer Financial Protection Bureau estimates that over&nbsp;450,000 federal student loan borrowers&nbsp;aged 62 and older may be impacted by this change. 
Furthermore, the resumption of student loan payments has had a significant impact on borrowers, with some seeing steep drops in their credit scores. This has created additional financial strain for retirees who are already facing the prospect of reduced Social Security benefits.
As retirees navigate these financial challenges, it&#8217;s important for them to explore all available resources, including charitable organizations that assist with health-care costs and food assistance programs. Additionally, retirees facing garnishments on their Social Security benefits&nbsp;may be able to prevent&nbsp;or stop the offset by proving a financial hardship or pursuing a discharge with their student loan servicer.
<ul class="wp-block-list">
<li>READ MORE: <a href="https://benzinga.com/news/politics/25/06/45716383/trump-administration-shuts-down-66-million-food-stamp-fraud-and-bribery-scheme-arrests-usda-employee-and-5-others" target="_blank" rel="noreferrer noopener">Trump Administration Shuts Down A $66 Million Food Stamp Fraud And Bribery Scheme, Arrests USDA Employee And 5 Others &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Personal Finance

June Social Security Checks Could Drop Sharply Due To Student Loan Garnishments — Experts Share Ways To Get Relief

ACRS

Aclaris Therapeutics Has Initiated A Randomized, Double-blind, Placebo-Controlled Phase 2 Trial Of Bosakitug (ATI-045) For Moderate-to-severe Atopic Dermatitis, Top Line Results Expected In The Second Half Of 2026

Guidance

SAIC

Science Applications Intl Affirms FY2026 Adj EPS Guidance of $9.10-$9.30 vs $10.24 Est; Affirms FY2026 Sales Guidance of $7.60B-$7.75B vs $7.93B Est

Earnings Beats

Earnings Misses

Science Applications Intl Q1 Adj. EPS $1.92 Misses $2.22 Estimate, Sales $1.88B Beat $1.87B Estimate

Raymond James analyst Frank Louthan downgrades Rackspace Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXT#NASDAQ">RXT</a>) from Outperform to Market Perform.

Downgrades

Raymond James Downgrades Rackspace Technology to Market Perform

KYMR

Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending

Office of Management and Budget Director Russell Vought is the latest high-profile figure to defend President Donald Trump's "big, beautiful bill," dismissing fears about Medicaid cuts as "ridiculous."
What Happened: In an interview <a href="https://edition.cnn.com/2025/06/01/politics/video/sotu-wh-budget-director-defends-trumps-big-beautiful-bill">on</a> CNN's State of the Union, Vought responded to allegations that the bill harms social safety nets that millions depend on: "We continue to work with people in the Senate as to working them through the specifics of the bill, what it does and what it doesn't do," he said.
"We'll continue to do that. And I think at the end of the day, the Senate will have a resounding vote in favor of a substantially similar bill."
Vought also responded to claims that millions would lose healthcare coverage, saying, "I think they're totally ridiculous. This is astroturf." "This bill will preserve and protect the programs, the social safety net, but it will make it much more common sense," he added.
He highlighted that the bill aims to target waste and misuse within the system rather than clamp down on benefits. "Look, one out of every $5 or $6 in Medicaid is improper. We have illegal immigrants on the program. We have able-bodied working adults that don't have a work requirement that they would have in TANF or even SNAP. And those are something that's very important to institute. That's what this bill does. No one will lose coverage as a result of this bill."
Responding to <a href="https://www.benzinga.com/news/25/05/45635854/elon-musk-disappointed-with-trumps-big-beautiful-bill-says-it-undermines-the-work-that-the-doge-team-is-doing">Elon Musk's criticism of the bill</a>, he said, "I love Elon, this bill doesn't increase the deficit or hurt the debt. In fact, it lowers it by $1.4 trillion."
See Also: <a href="https://www.benzinga.com/news/politics/25/06/45715447/xi-jinpings-china-dismisses-trumps-groundless-accusations-on-geneva-trade-deal-breach-vows-strong-retaliation">Xi Jinping&#8217;s China Dismisses Trump&#8217;s &#8216;Groundless&#8217; Accusations On Geneva Trade Deal Breach, Vows Strong Retaliation</a>
Why It Matters: The bill passed the House by one vote in May and is now facing major opposition in the Senate. Citing increases in deficit and spending cuts, many <a href="https://www.benzinga.com/news/25/05/45634893/gop-senators-threaten-to-block-trumps-tax-and-spending-bill-over-deficit-medicaid-cuts-and-debt-ceil">GOP Senators are mounting resistance</a>.
Meanwhile, Sen. Raphael Warnock (D-Ga.) criticized the new provisions as per which childless, able-bodied adults aged 19 to 64 are required to work or volunteer at least 20 hours a week to <a href="https://www.benzinga.com/25/05/45558613/house-advances-trumps-sweeping-one-big-beautiful-bill-after-key-medicaid-tax-and-border-security-changes">maintain eligibility for Medicaid.</a>
"What they're trying to do now is take this terrible experiment in Georgia, force it on the whole nation," Warnock said <a href="https://www.nbcnews.com/meet-the-press/video/warnock-says-trump-s-big-ugly-bill-threatens-millions-of-americans-healthcare-full-interview-240677957542">on</a> NBC's Meet the Press. "And what we will see as a result of that is a workforce that is sicker and poorer and an economy that's weaker."
In April, Trump said he would <a href="https://www.benzinga.com/government/25/04/45064937/donald-trump-threatens-to-veto-any-gop-bill-that-touches-medicaid-or-social-security-if-it-cuts-it-i-would-not-approve">"veto" any bill that includes cuts to Medicaid</a>. However, as the bill evolved, Medicaid cuts became central to its project of reducing federal spending, and <a href="https://www.benzinga.com/general/health-care/25/05/45345409/trumps-big-beautiful-bill-banks-on-huge-medicaid-cuts-as-its-cost-saving-centerpiece-see-who-risks-losing-coverage-under-the-gop-proposal">millions are set to lose coverage</a>.
Notably, Vought's claim about illegal immigrants being part of the Medicaid program is contested, since federally <a href="https://www.benzinga.com/news/25/05/45635594/trump-administration-claims-its-kicking-1-4-million-undocumented-immigrants-off-medicaid-but-grok-cl">funded Medicaid does not provide healthcare coverage for undocumented immigrants</a>, except in cases of emergency, as outlined in the 1996 PRWORA law.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/06/45715155/elizabeth-warren-calls-it-textbook-corruption-once-again-asks-for-probe-into-elon-musk-cashing-in-on-trump-tariffs">Elizabeth Warren Calls It &#8216;Textbook Corruption,&#8217; Once Again Asks For Probe Into Elon Musk &#8216;Cashing In&#8217; On Trump Tariffs</a></li>
</ul>
Photo courtesy: Shutterstock

Politics

Medicaid Cut Concerns Are 'Totally Ridiculous,' Says Trump's Budget Chief Russell Vought, Quips 'I Love Elon' While Countering Musk's Criticism

<ul>
<li>Deucrictibant data shows single-dose durability without symptom reoccurrence in the majority of HAE attacks treated</li>
<li>First-ever bradykinin B2 receptor mechanism-on-mechanism prophylactic/on-demand data supports potential for deucrictibant portfolio</li>
<li>Clinically validated biomarker assay has potential to eventually expand treatment opportunities of deucrictibant into additional forms of bradykinin-mediated angioedema</li>
<li>Epidemiologic data and cognitive interviews further elucidate the unmet needs in bradykinin-mediated angioedema</li>
</ul>
ZUG, Switzerland, June 02, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=tNakdJ3iY9GA5ZRSZLCNtXNQioaEjZsp0OwrGsq6X4XV-wlBWSC46QTBIJ0EbquksboUG1M0Fq1qsve56MBLg0GKwHwkDssayIncBx7sm2oW_xlkQfK03z8Hprtv5spcgE0VNyIiWS2a0QoTB4EIe-IKfx-sjBtZtblDaO6JalIfeA2EFwV2ps7Pzo0mu04XFeaYnAjBmlQkLfHgsKRLLUekGSZxDLvN8eij7Z8Cmo8=">Pharvaris</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHVS#NASDAQ">PHVS</a>), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced a summary of data that were presented at the 14th C1-Inhibitor Deficiency and Angioedema Workshop.

PHVS

Pharvaris Presents Key Findings On Bradykinin B2 Antagonists At Angioedema Workshop

Elon Musk announced the launch of the XChat messaging app with claimed Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) -style encryption, but cybersecurity experts are challenging the technical accuracy of the platform&#8217;s security assertions.
What Happened: Musk unveiled XChat on Sunday, promoting the app as built on the Rust programming language with Bitcoin-style encryption. The messaging platform features end-to-end encryption, disappearing messages, and file sharing capabilities without requiring phone numbers across all platforms.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">All new XChat is rolling out with encryption, vanishing messages and the ability to send any kind of file. Also, audio/video calling. This is built on Rust with (Bitcoin style) encryption, whole new architecture.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1929238157872312773?ref_src=twsrc%5Etfw">June 1, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
However, tech experts immediately questioned the encryption claims. Ian Miers, Assistant Professor of Computer Science at the University of Maryland, stated on X: &#8220;Bitcoin primarily uses signatures, not encryption. This is like saying, we decided to run our rocket on water, since NASA uses Hydrogen and Oxygen.&#8221; 
Miers explained that Bitcoin transactions are signed rather than encrypted, with all data between Bitcoin nodes remaining unencrypted to allow network interaction.
Miers further criticized the technical descriptions, noting: &#8220;Needless to say &#8216;Bitcoin style&#8217; and &#8216;Rust&#8217; are not descriptions of an encryption scheme, nor are they strong indicators of security for a messaging app.&#8221; 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Seriously, what is Bitcoin style encryption? Bitcoin primarily uses signatures, not encryption. This is like saying, we decided to run our rocket on water, since NASA uses Hydrogen and Oxygen. <a href="https://t.co/dWZhV6H4Tk">https://t.co/dWZhV6H4Tk</a>
&mdash; Ian Miers (@secparam) <a href="https://twitter.com/secparam/status/1929302662320635962?ref_src=twsrc%5Etfw">June 1, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/markets/equities/25/06/45716798/softbank-and-intel-set-to-launch-70-million-ai-memory-project-in-japan-to-slash-power-use">SoftBank And Intel Set To Launch $70 Million AI Memory Project In Japan To Slash Power Use</a>
Why It Matters: The launch comes amid ongoing security concerns surrounding Musk&#8217;s platforms. X experienced a massive <a href="https://www.benzinga.com/markets/25/04/44601197/massive-data-breach-at-elon-musks-x-reportedly-exposes-data-of-millions-of-accounts-by-far-the-largest-social-media-breach-ever">data breach</a> in April, exposing data from 201 million accounts in what SafetyDetectives called &#8220;by far the largest social media breach ever.&#8221; 
The breach included metadata such as account creation dates, locations, and post counts. Additionally, critics have raised questions about <a href="https://www.benzinga.com/general/social-media/25/04/44973207/elon-musks-critics-on-x-see-sudden-drop-in-visibility-raising-questions-about-platforms-free-speech-commitments">X&#8217;s content visibility algorithms</a> after several high-profile users reported dramatic reach declines following public disputes with Musk. 
In March, Musk&#8217;s <a href="https://www.benzinga.com/tech/25/03/44549314/elon-musk-acquires-his-own-social-media-platform-x-through-xai-in-33-billion-deal-says-combined-entity-now-worth-80-billion">xAI acquired X</a> for $33 billion, combining the social platform with his artificial intelligence venture.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/45716936/speaker-mike-johnson-says-4-8-million-wont-lose-medicaid-unless-they-choose-to-do-so-calls-gop-cuts-an-important-and-frankly-heroic-thing">Speaker Mike Johnson Says 4.8 Million Won&#8217;t Lose Medicaid &#8216;Unless They Choose To Do So,&#8217; Calls GOP Cuts &#8216;An Important And Frankly Heroic Thing&#8217;</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: JRdes / Shutterstock.com

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Elon Musk Launches XChat With Claimed Bitcoin-Style Encryption, But Expert Says It's Like Running A 'Rocket On Water'

Piper Sandler analyst Paul Newsome initiates coverage on American Integrity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AII#NYSE">AII</a>) with a Overweight rating and announces Price Target of $20.

Piper Sandler Initiates Coverage On American Integrity with Overweight Rating, Announces Price Target of $20

Piper Sandler analyst Paul Newsome initiates coverage on Aspen Insurance Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHL#NYSE">AHL</a>) with a Overweight rating and announces Price Target of $40.

Piper Sandler Initiates Coverage On Aspen Insurance Hldgs with Overweight Rating, Announces Price Target of $40

<ul>
<li>BNT327, BioNTech's PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set a new standard of care in multiple tumor types</li>
<li>The co-development and co-commercialization collaboration with a 50/50 profit/loss split will leverage both partners' expertise, resources and global footprint to accelerate BNT327's path towards potential regulatory approvals and market launches</li>
<li>BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.biontech.com%2Fen&amp;esheet=54263388&amp;newsitemid=20250602838823&amp;lan=en-US&amp;anchor=BioNTech+SE&amp;index=1&amp;md5=1b483074285e1f354b050f382ec03fb3">BioNTech SE</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>, "BioNTech"))) and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bms.com%2F&amp;esheet=54263388&amp;newsitemid=20250602838823&amp;lan=en-US&amp;anchor=Bristol+Myers+Squibb&amp;index=2&amp;md5=83c6c6eeb4378c5bb6d68c8e39efc4ff">Bristol Myers Squibb</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>, "BMS"))) today announced that the companies have entered into an agreement for the global co-development and co-commercialization of BioNTech's investigational bispecific antibody BNT327 across numerous solid tumor types. Under the agreement, BioNTech and BMS will work jointly to broaden and accelerate the development of this clinical candidate.

BNTX

BioNTech And Bristol Myers Squibb Partner To Advance Bispecific Antibody BNT327 For Solid Tumors

Mizuho analyst Ben Chaiken upgrades Red Rock Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRR#NASDAQ">RRR</a>) from Neutral to Outperform and maintains the price target from $50 to $50.

Upgrades

Mizuho Upgrades Red Rock Resorts to Outperform, Maintains Price Target to $50

Press Releases

GeneDx Enhances the Power of its Interpretation Platform with Artificial Intelligence (AI) Powered Gene Ranker to Enable Faster and More Efficient Clinical Analysis

Fast Company Recognizes GeneDx as One of the World's Most Innovative Companies

GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GeneDx Expands Commercial Footprint for Exome and Genome Testing with Inborn Errors of Immunity as a New Indication

GeneDx to Report First Quarter 2025 Financial Results on Wednesday, April 30, 2025

GeneDx to Acquire Fabric Genomics, Enabling Decentralized, AI-Powered Testing at Global Scale

GeneDx Reports First Quarter 2025 Financial Results and Business Highlights

GeneDx Announces Completion of Fabric Genomics Acquisition

GeneDx Publishes Pioneering Vision for Applying AI to Genomics to Improve and Expedite Diagnosis of Genetic Disease at Scale

GeneDx to Participate in Upcoming Investor Conferences

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Amedisys

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna Group

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

GeneDx Holdings

매도 수량

GeneDx Holdings (NASDAQ:WGS) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌